Association between sodium-glucose co-transporter-2 inhibito-rs and cardiac outcomes in cancer patients:a systematic review and meta-analysis
Xin-Yu ZHENG1
Nan ZHANG1
Bing-Xin XIE1
Guang-Ping LI1
Jian-Dong ZHOU2
Gary Tse3
Tong LIU1
1.Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease,Department of Cardiology,Tianjin Insti-tute of Cardiology,Second Hospital of Tianjin Medical University,Tianjin,China2.Department of Family Medicine and Primary Care,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong,China;Division of Health Sc-ience,Warwick Medical School,University of Warwick,United Kingdom3.Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease,Department of Cardiology,Tianjin Insti-tute of Cardiology,Second Hospital of Tianjin Medical University,Tianjin,China;School of Nursing and Health Studies,Hong Kong Metropolitan University,Hong Kong,China
摘要：BACKGROUND The beneficial effects of sodium-glucose co-transporter-2 inhibitors(SGLT2i)on adverse cardiac outcomes in diab-etic patients are well-established.However,the effects of SGLT2i against cancer therapy-related cardiotoxicity remain understudied.We investigated the association between SGLT2i and cardiac outcomes in cancer patients.
METHODS PubMed,Embase,and the Cochrane Library were searched from their inception until September 30,2024 for studies evaluating the effects of SGLT2i in patients with cancer.The primary outcomes included incident heart failure(HF),HF exacerbation,HF hospitalization,atrial fibrillation/atrial flutter(AF/AFL),myocardial infarction,and all-cause mortality.The secondary outcom-es included acute kidney injury and sepsis.Odds ratio(OR)with 95％CI was pooled.
RESULTS Thirteen studies with 85,596 patients were included.Compared to non-SGLT2i use,SGLT2i treatment was associated with lower risks of incident HF(OR=0.51,95％CI:0.32-0.79,P=0.003),HF exacerbation(OR=0.74,95％CI:0.63-0.87,P＜0.001),AF/AFL(OR=0.67,95％CI:0.55-0.82,P＜0.001),myocardial infarction(OR=0.61,95％CI:0.41-0.90,P=0.01),and all-cause mortali-ty(OR=0.44,95％CI:0.28-0.69,P＜0.001),but not for HF hospitalization(OR=0.58,95％CI:0.22-1.55,P=0.28).As for safety outcom-es,SGLT2i use was associated with lower risks of acute kidney injury(OR=0.68,95％CI:0.57-0.81,P＜0.001)and sepsis(OR=0.32,95％CI:0.23-0.44,P＜0.001).
CONCLUSIONS SGLT2i were associated with lower risks of incident HF,HF exacerbation,AF/AFL,myocardial infarction,all-cause mortality,acute kidney injury,and sepsis in cancer patients.
机标关键词：meta-analysisassociationbetweenreviewcancercardiacinhibito-rsoutcomes
论文发表日期：2025-10-30
在线出版日期：2025-11-19（本平台首次上网日期，不代表文献的发表时间）
页数：15( 844-858 )